Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 19, 2016.
The following 21 securities will be added to the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | AIMT | Aimmune Therapeutics, Inc. |
| Nasdaq | ARLZ | Aralez Pharmaceuticals Inc. |
| Nasdaq | AVXS | AveXis, Inc. |
| Nasdaq | BGNE | BeiGene, Ltd. |
| Nasdaq | BOLD | Audentes Therapeutics |
| Nasdaq | CLCD | CoLucid Pharmaceuticals |
| Nasdaq | CLSD | Clearside Biomedical, Inc. |
| Nasdaq | CYTK | Cytokinetics, Incorporated |
| Nasdaq | EDIT | Editas Medicine, Inc. |
| Nasdaq | GBT | Global Blood Therapeutics |
| Nasdaq | ITCI | Intra-Cellular Therapies |
| Nasdaq | LOXO | Loxo Oncology, Inc. |
| Nasdaq | MNOV | Medicinova Inc |
| Nasdaq | NERV | Minerva Neurosciences |
| Nasdaq | NH | NantHealth, Inc. |
| Nasdaq | NTLA | Intellia Therapeutics, Inc. |
| Nasdaq | NVCR | NovoCure Limited |
| Nasdaq | ONVO | Organovo Holdings Inc |
| Nasdaq | OPK | OPKO Health, Inc. |
| Nasdaq | PRTK | Paratek Pharmaceuticals, Inc. |
| Nasdaq | RGNX | REGENXBIO Inc. |
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | ADHD | Alcobra Ltd. |
| Nasdaq | ADVM | Adverum Biotechnologies, Inc. |
| Nasdaq | AFMD | Affimed N.V. |
| Nasdaq | AGTC | Applied Genetic Technologies Corporation |
| Nasdaq | ANTH | Anthera Pharmaceuticals, Inc. |
| Nasdaq | CARA | Cara Therapeutics, Inc. |
| Nasdaq | CASC | Cascadian Therapeutics, Inc. |
| Nasdaq | CHMA | Chiasma, Inc. |
| Nasdaq | CMRX | Chimerix, Inc. |
| Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
| Nasdaq | CXRX | Concordia International Corp. |
| Nasdaq | DNAI | ProNAi Therapeutics, Inc. |
| Nasdaq | DRNA | Dicerna Pharmaceuticals, Inc. |
| Nasdaq | DRRX | DURECT Corporation |
| Nasdaq | ECYT | Endocyte, Inc. |
| Nasdaq | EGLT | Egalet Corporation |
| Nasdaq | FLKS | Flex Pharma, Inc. |
| Nasdaq | IMDZ | Immune Design Corp. |
| Nasdaq | IMGN | ImmunoGen, Inc. |
| Nasdaq | INFI | Infinity Pharmaceuticals, Inc. |
| Nasdaq | ITEK | Inotek Pharmaceuticals Corporation |
| Nasdaq | KMPH | KemPharm, Inc. |
| Nasdaq | LIFE | aTyr Pharma, Inc. |
| Nasdaq | MNKD | MannKind Corporation |
| Nasdaq | NDRM | NeuroDerm Ltd. |
| Nasdaq | NEOS | Neos Therapeutics, Inc. |
| Nasdaq | OCUL | Ocular Therapeutix, Inc. |
| Nasdaq | OREX | Orexigen Therapeutics, Inc. |
| Nasdaq | OSIR | Osiris Therapeutics, Inc. |
| Nasdaq | OVAS | OvaScience Inc. |
| Nasdaq | QURE | uniQure N.V. |
| Nasdaq | RGLS | Regulus Therapeutics Inc. |
| Nasdaq | SCLN | SciClone Pharmaceuticals, Inc. |
| Nasdaq | TKAI | Tokai Pharmaceuticals, Inc. |
| Nasdaq | TTPH | Tetraphase Pharmaceuticals, Inc. |
| Nasdaq | VTL | Vital Therapies, Inc. |
| Nasdaq | ZFGN | Zafgen, Inc. |
